AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00275041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT00275041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00053014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Study NCT00053014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00053014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Study NCT00053014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Study NCT00053014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00053014 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04507490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: 315/5000 application of whole body vibration with pre-established parameters for each group. All patients will participate in all groups, an interval of at least one week. They will be instructed to climb on the platform and to position a semi knee flexion and remain stationary during the vibration
Study NCT04507490 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Whole body vibration
Description: 315/5000 application of whole body vibration with pre-established parameters for each group. All patients will participate in all groups, an interval of at least one week. They will be instructed to climb on the platform and to position a semi knee flexion and remain stationary during the vibration
Study NCT02568852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined anaesthesia
Description: Laparoscopic cholecystectomy under 10 mmHg pressure
Study NCT02568852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: Laparoscopic cholecystectomy under 10 mmHg pressure
Study NCT02931747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are received Placebo once daily for 16 weeks.
Study NCT02931747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bacopa Monnieri 300 mg/day
Description: Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
Study NCT02931747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bacopa Monnieri 600 mg/day
Description: Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.
Study NCT04339725 — intervention group
Intervention type: OTHER
Intervention: DNA extraction
Description: Extraction fecal DNA and compare disease group to normal group
Study NCT01355224 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic
Description: Relative risk estimates will be presented based on individuals' risk for obesity based on FTO genotype results.
Study NCT01355224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Relative risk estimates will be presented based on individuals' risk for obesity due to lifestyle factors.
Study NCT01473355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™ TX
Description: OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
Study NCT01848795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier Gastrointestinal Liner
Description: Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
Study NCT01848795 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Easy life balloon
Description: Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
Study NCT04450004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular Vaccine
Description: Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.
Study NCT02054663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patients on ticagrelor following an acute coronary syndrome, being transitioned to clopidogrel will be randomized to either a one time 600mg bolous dose of clopidogrel followed by 75mg daily or just starting at 75mg daily without a bolous dose.
Study NCT01314144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively
Study NCT02928081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Description: Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)
Study NCT02928081 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard lymphadenectomy
Description: Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)
Study NCT00063986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE)
Description: Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Study NCT02942693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib will be used as induction therapy in experimental arm.
Study NCT03936712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink
Description: Each participant visited the laboratory for two formal test sessions, drinking a caffeine-containing ED (RB) and a caffeine and taurine free beverage drink (PL). All sessions were arranged in the early evening hours to avoid any time of day effects. The two definitive test sessions were separated by an interval of seven days to allow sufficient recovery between tests and to ensure caffeine washout. To avoid identification, two opaque and unmarked cans of RB or PL were ingested by each participant (i.e., 500 mL) in the presence of a researcher. The two drinks were similar in volume, texture, and appearance. One can of RB drink (i.e., 250ml) contained 80 mg of caffeine, 1 g of taurine, 27 g of carbohydrates, 0.6 g of protein, 5 mg vitamin B6 and 487 kJ of energy.
Study NCT03936712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drink
Description: The PL drink was prepared by an agri-food engineer; it did not contain any caffeine or taurine, but comprised carbonated water, carbohydrates, citric acid lemon juice reconstituted from concentrate (1 %), supplemented by flavorings, of sodium citrate, acesulfame K, sucralose, potassium sorbate and RB (a flavoring that contains propylene glycol E1520 (0.23 mL).
Study NCT01345916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 100/6 NEXT DPI® 2 months
Description: CHF 1535 100/6 NEXT DPI® 2 months
Study NCT01345916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 100/6 pMDI 2 months
Description: CHF 1535 100/6 pMDI 2 months
Study NCT01345916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP DPI 2 months
Description: BDP DPI 2 months
Study NCT04737096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
Study NCT04737096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04737096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS
Study NCT04737096 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: tDCS
Study NCT02942693 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Particle Therapy
Description: Same total dose and fractionation will be used in both arms.
Study NCT01925482 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 6%CO2, 25%O2, balance N2
Description: exposure of middle ear to gas
Study NCT01925482 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 6% CO2, 0%O2, balance N2
Description: exposure of middle ear to gas
Study NCT03463408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: 240 mg every 2 weeks
Study NCT03463408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: 1 mg/kg every 6 weeks
Study NCT01925482 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 20%CO2, 6%O2, balance N2
Description: exposure of middle ear to gas
Study NCT01925482 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0%CO2, 6%O2, balance N2
Description: exposure of middle ear to gas
Study NCT01925482 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 6% CO2, 6%O2, balance N2
Description: exposure of middle ear to gas
Study NCT01925482 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 6%CO2, 6%O2, 0%N2, balance argon
Description: exposure of middle ear to gas
Study NCT02382614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiration Valve System
Study NCT03374891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational video and/or handout
Description: The intervention includes a video and/or handout (whichever is easier for the participant) that will give information about defibrillators and about other patients' experiences with their decisions about defibrillators.
Study NCT02040298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clemastine
Description: 4mg tablet twice daily
Study NCT02040298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily
Study NCT01308489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo posterior spinal tumor resection
Study NCT01308489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo anterior and posterior spinal tumor resection
Study NCT01308489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT03580200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trigger Point Dry Needling
Description: For the purposes of this study, the term trigger point dry needling will be used to describe deep dry needling of muscle tissue. The goal of trigger point dry needling is to eliminate myofascial trigger points within muscle tissue, thereby reducing pain as well as improving motor control and function (Caramagno et al., 2015; Dommerholt et al., 2006; Shah et al., 2015). Trigger point dry needling utilizes a solid filiform needle and focuses on the penetration of a palpable myofascial trigger point at various depths. The needle is then manipulated within the tissue in an attempt to elicit a localized twitch response. Once the localized twitch response has ended, the needle is removed and another myofascial trigger point is located.
Study NCT00824967 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training and valuation of the treating personnel
Description: Training and valuation of the treating personnel
Study NCT00122070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate
Description: Dosage can vary from 50 to 150 mg at PI's discretion
Study NCT00948194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
Study NCT00410514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral
Study NCT00410514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT02853786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LENA and advice
Description: Language recording with the LENA device, with the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
Study NCT02853786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LENA without advice
Description: Language recording with the LENA device. Regular speech therapy follow blindly the results of LENA
Study NCT03734770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Progesterone
Description: Subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference).
Study NCT03734770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: Micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours).
Study NCT02269904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil Implants
Description: Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
Study NCT02269904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xelox regimes
Description: Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
Study NCT01012037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin low dose
Description: patient to receive tablets containing low dose linagliptin twice daily
Study NCT01012037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patient to receive placebo tablet(s) matching linagliptin
Study NCT01012037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin medium dose
Description: patient to receive a tablet containing medium dose linagliptin once daily
Study NCT02186535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D and Calcium
Study NCT02617706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epiflo
Description: Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
Study NCT04506385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: In the first phase: 10 subjects have added in the diet a daily dose of 1 billion of freeze-dried LDD01 probiotics (A arm), 12 individuals are supplemented with a daily dose of 1 billion of the DLBL mix (B arm). In the second phase: 10 individuals are supplemented with a daily low dose of probiotics blend (C arm) and 10 individuals are supplemented with a daily high dose of probiotics blend (D arm).
Study NCT02918721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lidocaine
Description: Intradermal injection
Study NCT02918721 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Intradermal injection
Study NCT02462122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: Lotion
Study NCT02462122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Vehicle Lotion
Description: Lotion
Study NCT05387135 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000).
Study NCT05387135 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000).
Study NCT02928250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carnosine
Description: Patients in intervention group received carnosine capsules orally daily
Study NCT02928250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in placebo group received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
Study NCT04694014 — intervention group
Intervention type: BEHAVIORAL
Intervention: EI Open ended Pre-Survey and Semi Structured Interview
Description: Provide Interview questions via online survey with informed consent to the participants then contact a 60 minute member checking interview in person or virtually via recorded Zoom sessions for each participant
Study NCT04694014 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral and Cognitive Assessment
Description: Use Predictive index for both cognitive and behavioral assessment of the paticipants
Study NCT04694014 — intervention group
Intervention type: BEHAVIORAL
Intervention: Geneva Emotional Competence Test (GECO)
Description: Administer the Geneva Emotional Competence Test to each participant
Study NCT03273894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coagulation testing
Description: * body temperature before the intervention~* body temperature during the intervention including the way of measuring, each 15 minutes~* body temperature at the end of surgery, signs of the patient's heat discomfort~* body temperature during resting time in the postanesthesia care~* standard coagulation tests + EXTEM, FIBTEM - after anesthesia induction~* blood sampling for standard coagulation tests (prior to the end of the surgical intervention) + EXTEM, FIBTEM.~* if body temperature is below 34°C, two sets of ROTEM tests are run: one at patient's body temperature, following by another one at a standard temperature (37°C).
Study NCT04850885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml
Description: The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
Study NCT04850885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml
Description: The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
Study NCT03479658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Two schools with four classes/groups of 4th degree of children will participate in the pilot study (i.e., age of children 9-10 years old). One of them has two physical education (PE) sessions per week and the other has only one PE session per week. In the school with two PE sessions, two classes will be randomly assigned to HIIT (2 sessions/week) +nutrition group, and two to the nutrition group. Similarly, in the school with one PE session per week, two classes will be randomly assigned to HIIT (1 session/week) + nutrition and two classes to the nutrition goup. Both HIIT and nutritional education sessions will be integrated integrated into the physical education and sciences sessions of the schools. The duration of the intervention will be of eight weeks.
Study NCT03479658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: School-based nutritional education on healthy dietary habits
Study NCT03479658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional education
Description: School-based nutritional education on healthy dietary habits
Study NCT03580486 — intervention group
Intervention type: OTHER
Intervention: The squares test
Description: The squares test (ST) originally used in handedness is modified. The ST is a reliable, not time-consuming and easy to administer test for evaluated hand function.
Study NCT04708574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention